Gail N Brown

US Patent:

20040138140, Jul 15, 2004

Filed:

Nov 14, 2003

Appl. No.:

10/714593

Inventors:

Hua Xu - Sunnyvale CA, US
Gail Brown - Woodside CA, US
Steven Schow - Redwood City CA, US
James Keck - Redwood City CA, US

Assignee:

Telik, Inc.

International Classification:

A61K038/05

US Classification:

514/018000

Abstract:

A method of combination cancer therapy in a mammal, especially a human, by administering a therapeutically effective amount of a GST-activated anticancer compound and a therapeutically effective amount of another anticancer therapy, that is, an anticancer therapy that is not a treatment with a GST-activated anticancer compound (including chemotherapy, molecular targeted therapy, biologic therapy, and radiotherapy, used as monotherapy or in combination). Pharmaceutical compositions, products, and kits for the method. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. A method of potentiating an anticancer therapy in a mammal, especially a human, comprising administering a therapeutically effective amount of a GST-activated anticancer compound to the mammal being treated with the anticancer therapy. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably TLK286, especially as the hydrochloride salt.

US Patent:

20050261202, Nov 24, 2005

Filed:

May 19, 2005

Appl. No.:

11/133833

Inventors:

Gail Brown - Woodside CA, US
James Keck - Redwood City CA, US
Michael Wick - Woodside CA, US

International Classification:

A61K038/05

US Classification:

514018000

Abstract:

A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.

US Patent:

20080159980, Jul 3, 2008

Filed:

Oct 15, 2007

Appl. No.:

11/872659

Inventors:

Hua Xu - Sunnyvale CA, US
Gail L. Brown - Woodside CA, US
Steven R. Schow - Redwood City CA, US
James G. Keck - Redwood City CA, US

International Classification:

A61K 31/664
A61K 38/20
A61K 38/21
A61K 39/395
A61K 31/704
A61P 35/00

US Classification:

424 852, 514118, 424 854, 4241411, 514 34

Abstract:

A method of combination cancer therapy in a mammal, especially a human, by administering a therapeutically effective amount of a GST-activated anticancer compound and a therapeutically effective amount of another anticancer therapy, that is, an anticancer therapy that is not a treatment with a GST- activated anticancer compound (including chemotherapy; molecular targeted therapy; biologic therapy; and radiotherapy, used as monotherapy or in combination). Pharmaceutical compositions, products, and kits for the method. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. A method of potentiating an anticancer therapy in a mammal, especially a human, comprising administering a therapeutically effective amount of a GST-activated anticancer compound to the mammal being treated with the anticancer therapy. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably TLK, especially as the hydrochloride salt.

US Patent:

20080166428, Jul 10, 2008

Filed:

Oct 15, 2007

Appl. No.:

11/872662

Inventors:

Gail L. Brown - Woodside CA, US
James G. Keck - Redwood City CA, US
Michael M. Wick - Woodside CA, US

International Classification:

A61K 33/24
A61K 38/05

US Classification:

424649, 514 7

Abstract:

A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.

US Patent:

20110301102, Dec 8, 2011

Filed:

May 16, 2011

Appl. No.:

13/108752

Inventors:

Gail L. Brown - Woodside CA, US

International Classification:

A61K 38/06
A61P 7/00
A61P 43/00

US Classification:

514 219

Abstract:

This invention relates to specific treatment regimens for treating myelodysplastic syndrome.

US Patent:

20110301198, Dec 8, 2011

Filed:

May 16, 2011

Appl. No.:

13/108754

Inventors:

Gail L. Brown - Woodside CA, US
Lixin Meng - Cupertino CA, US

International Classification:

A61K 31/225
A61P 7/00
A61K 31/454

US Classification:

514323, 514533

Abstract:

This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide.

US Patent:

20110301199, Dec 8, 2011

Filed:

May 16, 2011

Appl. No.:

13/108756

Inventors:

Gail L. Brown - Woodside CA, US
Lixin Meng - Cupertino CA, US

International Classification:

A61K 31/454
A61P 7/00

US Classification:

514323

Abstract:

This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof in patients who have been treated with a DNA methyltransferase inhibitor by a combination of ezatiostat or a salt thereof and lenalidomide.

US Patent:

20120288554, Nov 15, 2012

Filed:

May 12, 2011

Appl. No.:

13/106702

Inventors:

Gail L. Brown - Woodside CA, US

International Classification:

A61K 9/127
C07F 9/24
A61P 35/00
A61K 39/395
A61K 31/675
A61K 31/664
A61K 31/69

US Classification:

424450, 514118, 558171, 514 64, 4241331, 514110

Abstract:

Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and elotuzumab.